Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Artemether-lumefantrine, mefloquine and atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria in travellers: A retrospective comparative study of efficacy and treatment failures

V. Grebenyuk, F. Stejskal, E. Nohýnková, I. Zicklerová, L. Richterová, H. Roháčová, H. Rozsypal, M. Trojánek

. 2023 ; 52 (-) : 102549. [pub] 20230217

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23010672

BACKGROUND: The aim of this study was to evaluate the rates of parasitaemia clearance and the prevalence of treatment failure in patients with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (AL), mefloquine (MQ), and atovaquone-proguanil (AP). METHOD: The retrospective descriptive study included adult patients with uncomplicated P. falciparum malaria treated at the University Hospital Bulovka in Prague from 2006 to 2019. Parasitaemia clearance was estimated using a linear regression model. RESULTS: The study included 72 patients with a median age of 33 years (IQR 27-45) and a male to female ratio of 3.2:1. Thirty-six patients (50.0%) were treated with AL, 27 (37.5%) with MQ and 9 (12.5%) with AP. The proportion of VFR and migrants was 22.2% with no significant differences among the three groups. The median time to the parasitaemia clearance was two days (IQR 2-3) in patients treated with AL versus four days in the MQ (IQR 3-4) and AP (IQR 3-4) groups, p < 0.001. The clearance rate constant was 3.3/hour (IQR 2.5-4.0) for AL, 1.6/hour (IQR 1.3-1.9) for MQ, and 1.9/hour (IQR 1.3-2.4) for AP, p < 0.001. Malaria recrudescence occurred in 5/36 (13.9%) patients treated with AL and in no patients treated with MQ or AP. CONCLUSIONS: The findings demonstrate the superior efficacy of AL compared to other oral antimalarials in early malaria treatment. However, we observed a higher rate of late treatment failure in patients treated with AL than previously reported. This issue warrants further investigation of possible dose adjustments, extended regimens, or alternative artemisinin-based combinations.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010672
003      
CZ-PrNML
005      
20230801132557.0
007      
ta
008      
230718s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.tmaid.2023.102549 $2 doi
035    __
$a (PubMed)36792022
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Grebenyuk, Vyacheslav $u Department of Infectious Diseases, 2nd Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious Diseases and Travel Medicine, University Hospital Motol, V Úvalu 84, 150 06, Prague, Czech Republic. Electronic address: vyacheslav.grebenyuk@fnmotol.cz
245    10
$a Artemether-lumefantrine, mefloquine and atovaquone-proguanil in the treatment of uncomplicated Plasmodium falciparum malaria in travellers: A retrospective comparative study of efficacy and treatment failures / $c V. Grebenyuk, F. Stejskal, E. Nohýnková, I. Zicklerová, L. Richterová, H. Roháčová, H. Rozsypal, M. Trojánek
520    9_
$a BACKGROUND: The aim of this study was to evaluate the rates of parasitaemia clearance and the prevalence of treatment failure in patients with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (AL), mefloquine (MQ), and atovaquone-proguanil (AP). METHOD: The retrospective descriptive study included adult patients with uncomplicated P. falciparum malaria treated at the University Hospital Bulovka in Prague from 2006 to 2019. Parasitaemia clearance was estimated using a linear regression model. RESULTS: The study included 72 patients with a median age of 33 years (IQR 27-45) and a male to female ratio of 3.2:1. Thirty-six patients (50.0%) were treated with AL, 27 (37.5%) with MQ and 9 (12.5%) with AP. The proportion of VFR and migrants was 22.2% with no significant differences among the three groups. The median time to the parasitaemia clearance was two days (IQR 2-3) in patients treated with AL versus four days in the MQ (IQR 3-4) and AP (IQR 3-4) groups, p < 0.001. The clearance rate constant was 3.3/hour (IQR 2.5-4.0) for AL, 1.6/hour (IQR 1.3-1.9) for MQ, and 1.9/hour (IQR 1.3-2.4) for AP, p < 0.001. Malaria recrudescence occurred in 5/36 (13.9%) patients treated with AL and in no patients treated with MQ or AP. CONCLUSIONS: The findings demonstrate the superior efficacy of AL compared to other oral antimalarials in early malaria treatment. However, we observed a higher rate of late treatment failure in patients treated with AL than previously reported. This issue warrants further investigation of possible dose adjustments, extended regimens, or alternative artemisinin-based combinations.
650    _2
$a dospělí $7 D000328
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a antimalarika $x škodlivé účinky $7 D000962
650    _2
$a meflochin $x terapeutické užití $x škodlivé účinky $7 D015767
650    _2
$a kombinace léků artemether a lumefantrin $x terapeutické užití $7 D000077611
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a artemether $x terapeutické užití $7 D000077549
650    12
$a tropická malárie $x farmakoterapie $x epidemiologie $7 D016778
650    _2
$a fixní kombinace léků $7 D004338
650    12
$a malárie $x farmakoterapie $7 D008288
650    _2
$a neúspěšná terapie $7 D017211
650    _2
$a Plasmodium falciparum $7 D010963
650    _2
$a ethanolaminy $x terapeutické užití $7 D004983
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stejskal, František $u Department of Infectious Diseases, 2nd Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious Diseases, Regional Hospital Liberec, Husova 10, 460 63, Liberec, Czech Republic; Institute of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studničkova 7, 128 00, Prague, Czech Republic
700    1_
$a Nohýnková, Eva $u Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic; Institute of Immunology and Microbiology, 1st Faculty of Medicine, Charles University, Studničkova 7, 128 00, Prague, Czech Republic; National Reference Laboratory for the Diagnosis of Tropical Parasitic Infections, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious and Tropical Diseases, 1st Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic
700    1_
$a Zicklerová, Ivana $u National Reference Laboratory for the Diagnosis of Tropical Parasitic Infections, Budínova 2, 180 81, Prague, Czech Republic; Department of Clinical Microbiology, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic
700    1_
$a Richterová, Lenka $u National Reference Laboratory for the Diagnosis of Tropical Parasitic Infections, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious and Tropical Diseases, 1st Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic; Department of Clinical Microbiology, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic; Department of Microbiology of the 3rd Faculty of Medicine, Charles University, University Hospital Královské Vinohrady and the National Institute of Public Health, Šrobárova 50, 100 34, Prague, Czech Republic
700    1_
$a Roháčová, Hana $u Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic
700    1_
$a Rozsypal, Hanuš $u Department of Infectious Diseases, University Hospital Bulovka, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious and Tropical Diseases, 1st Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic
700    1_
$a Trojánek, Milan $u Department of Infectious Diseases, 2nd Faculty of Medicine, Charles University, Budínova 2, 180 81, Prague, Czech Republic; Department of Infectious Diseases and Travel Medicine, University Hospital Motol, V Úvalu 84, 150 06, Prague, Czech Republic
773    0_
$w MED00008669 $t Travel medicine and infectious disease $x 1873-0442 $g Roč. 52, č. - (2023), s. 102549
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36792022 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132554 $b ABA008
999    __
$a ok $b bmc $g 1963243 $s 1196937
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 52 $c - $d 102549 $e 20230217 $i 1873-0442 $m Travel medicine and infectious disease $n Travel Med Infect Dis $x MED00008669
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options